- CH₣416.88m
- CH₣632.48m
- CH₣483.90m
- 59
- 50
- 34
- 42
Annual cashflow statement for medmix AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 9.6 | 44 | 11.6 | 0.7 | -6.4 |
Depreciation | |||||
Non-Cash Items | 7.9 | 20.9 | 48.9 | 11.6 | 17.9 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -9.9 | -29.3 | -64.1 | -14.6 | 13.5 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 50.7 | 87.3 | 47.5 | 56.1 | 86.6 |
Capital Expenditures | -43.1 | -31.9 | -38.6 | -52.9 | -48.5 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 47.6 | 28.6 | -18.4 | -27.7 | -3 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Sale of Intangible Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 4.5 | -3.3 | -57 | -80.6 | -51.5 |
Financing Cash Flow Items | — | 0.9 | 0.2 | -1.7 | 0.1 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -42.9 | 112 | 116 | -154 | -48.6 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 10.5 | 195 | 104 | -183 | -12.5 |